Novartis AG with ticker code (NVS) now have 4 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 105 and 97 and has a mean target at 102. Given that the stocks previous close was at 86.75 this now indicates there is a potential upside of 17.6%. The 50 day moving average now sits at 85.87 and the 200 moving average now moves to 85.79. The market capitalisation for the company is $190,470m. Find out more information at: https://www.novartis.com
The potential market cap would be $223,953m based on the market concensus.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
